ARCHIVES

Cancer center directors to develop blueprint for progress that’s “honest,” M.D. Anderson’s John Mendelsohn says.

This article is from The Cancer Letter archive.

Vol. 31 No. 43 | November 23, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

May 14, 2010

ASCO Defines Clinically Meaningful Outcomes

April 25, 2013

Conversation with The Cancer Letter: Einhorn: “I Still Harbor Hope For Similar Success Stories”

October 24, 2014

NCI-Approved Clinical Trials

September 29, 2006

In Brief :Three Named to Leadership Posts At St. Jude; Mitchell Weiss Appointed Chair of Hematology

June 11, 2014

Committee Drafts QRA Definition

November 19, 1982